First-line therapy for immune thrombocytopenic purpura (ITP) includes which of the following?

First-line therapy for immune thrombocytopenic purpura (ITP) includes which of the following?

• A. Corticosteroids
• B. Splenectomy
• C. Thrombopoietin-receptor agonists
• D. Rituximab

Answer: (A)

When managing ITP, the goal is to raise the platelet count quickly to prevent bleeding, and corticosteroids do this most effectively as an initial approach. They blunt the immune response that targets platelets by reducing autoantibody production and decreasing the clearance of platelets by macrophages, leading to a rapid rise in platelets in many patients. In adults and children, typical regimens like prednisone at about 1 mg/kg daily or a short course of high-dose dexamethasone can produce a response within days to a couple of weeks, allowing tapering as counts improve. The broad, well-established effect, plus the ease of use and cost-effectiveness, make corticosteroids the standard first-line therapy. Other options—splenectomy, rituximab, and thrombopoietin-receptor agonists—are generally reserved for patients who do not respond to steroids or have chronic/refractory disease, since they involve surgical risk, slower onset, potential infections, or the need for ongoing treatment.

When managing ITP, the goal is to raise the platelet count quickly to prevent bleeding, and corticosteroids do this most effectively as an initial approach. They blunt the immune response that targets platelets by reducing autoantibody production and decreasing the clearance of platelets by macrophages, leading to a rapid rise in platelets in many patients. In adults and children, typical regimens like prednisone at about 1 mg/kg daily or a short course of high-dose dexamethasone can produce a response within days to a couple of weeks, allowing tapering as counts improve. The broad, well-established effect, plus the ease of use and cost-effectiveness, make corticosteroids the standard first-line therapy. Other options—splenectomy, rituximab, and thrombopoietin-receptor agonists—are generally reserved for patients who do not respond to steroids or have chronic/refractory disease, since they involve surgical risk, slower onset, potential infections, or the need for ongoing treatment.